Is Semaglutide safe?
- Name
- Semaglutide
- Also known as
- Ozempic, Wegovy, Rybelsus
- Class
- GLP-1 receptor agonist
- Verdict
- Approved Approved by a regulator for a human indication
- Human evidence
- Strong
- Updated
- October 2026
What is Semaglutide?
Semaglutide is a modified version of GLP-1, a hormone your gut releases after eating. It slows stomach emptying, lowers appetite and helps the pancreas release insulin when blood sugar is high. It is sold as a weekly injection (Ozempic for type 2 diabetes, Wegovy for chronic weight management) and as a daily tablet (Rybelsus, type 2 diabetes). Unlike most peptides discussed online, it went through full phase 3 trials and regulatory review.
What it is claimed to do
These are the uses Semaglutide is promoted for. Listing a claim is not endorsing it — the next section is where each one meets the evidence.
- Blood sugar control in type 2 diabetes
- Chronic weight management in adults with obesity, or overweight plus a weight-related condition
- Lowering the risk of major cardiovascular events in people with established heart disease and overweight or obesity
What the human evidence shows
In the STEP 1 trial (New England Journal of Medicine, 2021), adults with overweight or obesity and no diabetes who took semaglutide for 68 weeks lost an average of about 15% of body weight, compared with about 2.4% on placebo, alongside lifestyle support. The SELECT trial (New England Journal of Medicine, 2023) found that semaglutide reduced major cardiovascular events by about 20% in adults with heart disease and overweight or obesity who did not have diabetes. Results depend on staying on the medicine: in follow-up studies, many people regained a large share of the weight after stopping.
Known risks and side effects
- Common: nausea, vomiting, diarrhea, constipation and abdominal pain, especially when the dose is increased.
- Serious but less common: pancreatitis, gallbladder disease, and kidney injury linked to dehydration from vomiting or diarrhea.
- In diabetes: worsening of diabetic eye disease can occur with rapid blood-sugar improvement, and low blood sugar is more likely when combined with insulin or sulfonylureas.
- Thyroid C-cell tumours appeared in rodent studies, which is why the US label carries a boxed warning and why it is not used by people with a personal or family history of medullary thyroid carcinoma or MEN 2.
- Regulators have reviewed rare reports of sudden vision loss (NAION); ask your prescriber how this applies to you.
- Unapproved copies carry added risks: dosing errors, wrong or contaminated ingredients, and counterfeit pens.
Legal status
Regulatory status as of October 2026. Approval, prescription status and compounding restrictions change without notice, and the two countries move independently. Check the regulator directly before relying on any of it.
United States
- Approved for human use
- Yes — approved by the FDA for at least one indication
- Prescription only
- Yes — available only on a prescription
FDA-approved prescription drug. The FDA states that compounded and other unapproved semaglutide products are not FDA approved and are not reviewed for safety, effectiveness or quality. As of May 31, 2026 the FDA had received 990 adverse event reports for compounded semaglutide, some requiring hospitalization and possibly linked to dosing errors. It also says semaglutide sodium and semaglutide acetate salts should not be used to compound semaglutide.
Canada
- Approved for human use
- Yes — approved by Health Canada for at least one indication
- Prescription only
- Yes — available only on a prescription
Authorized by Health Canada as a prescription drug. Health Canada approved its first generic semaglutide on April 28, 2026 and a second (Apotex, a generic of Ozempic for type 2 diabetes) on May 1, 2026, with further submissions under review. Health Canada's January 2026 advisory warns that unauthorized semaglutide and tirzepatide products sold online or on social media have not been assessed for safety, effectiveness or quality, and advises using only a licensed pharmacy and checking for a Drug Identification Number (DIN).
Who should avoid Semaglutide
- You are pregnant, planning pregnancy, or breastfeeding.
- You or a close relative have had medullary thyroid carcinoma or MEN 2.
- You have had pancreatitis or have severe stomach or bowel problems, unless your prescriber says otherwise.
- You are considering a product that does not come from a licensed pharmacy, or that does not show a DIN.
Frequently asked questions
Is semaglutide safe?
Semaglutide has been studied in tens of thousands of people and is approved for specific uses under medical supervision. It has common digestive side effects and some serious but less common risks, so safety depends on whether you are a good candidate and how it is prescribed and monitored. Copies from unlicensed sources are a separate and higher-risk category.
Is compounded semaglutide the same as Ozempic or Wegovy?
No. The FDA says compounded products are not FDA approved and are not reviewed for safety, effectiveness or quality, and it has received hundreds of adverse event reports, some linked to dosing errors. In Canada, generic semaglutide products are approved by Health Canada and carry a DIN; those are different from unlicensed or compounded copies.
What happens if I stop taking it?
Appetite and weight typically return toward baseline for many people. Treatment is usually considered long term, so discuss your plan with your prescriber before you start.
Sources
- Health CanadaHealth Canada: second generic semaglutide approved (May 2026)
- Health CanadaHealth Canada: first generic semaglutide approved (April 2026)
- Health Canada (Recalls & Safety Alerts)Health Canada advisory on fake or unauthorized GLP-1 drugs (January 2026)
- FDAFDA: concerns with unapproved GLP-1 drugs used for weight loss
- PubMedSTEP 1 trial, New England Journal of Medicine (2021)
- PubMedSELECT trial, New England Journal of Medicine (2023)